
    
      This study was an open label, randomized, three-treatment, three-period, six-sequence,
      single-dose, crossover pharmacokinetic study planned on 36 healthy, adult, human subjects
      under fasting conditions. However 34 subjects were enrolled and 33 subjects completed all the
      periods of the study. All periods were separated by a washout of seven days As per protocol
      (Appendix 1), enough healthy, adult, human subjects were to be enrolled in the study to allow
      the dosing of 36 subjects in the first period. 34 subjects were enrolled and 33 subjects
      completed all the periods of study
    
  